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Patients with left-sided breast cancer are at risk of cardiac toxicity because of cardiac irra-
diation during radiotherapy with the conventional 3-dimensional conformal radiotherapy
technique. In addition, many patients may receive chemotherapy prior to radiation, which
may damage the myocardium and may increase the potential for late cardiac complica-
tions. New radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) may
decrease the risk of cardiac toxicity because of the steep dose gradient limiting the volume
of the heart irradiated to a high dose. Image-guided radiotherapy (IGRT) is a new technique
of IMRT delivery with daily imaging, whichmay further reduce excessive cardiac irradiation.
Preliminary results of IGRT for cardiac sparing in patients with left-sided breast cancer are
promising and need to be investigated in future prospective clinical studies.
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CARDIAC TOXICITY FOLLOWING LEFT BREAST CANCER
IRRADIATION
Patients with left-sided breast cancer are at risk of long-term
cardiac complications following irradiation. In a study of 2168
breast cancer patients who had post-operative breast irradiation,
the risk of major coronary events was significantly higher among
the patients who had radiation to the left breast. The rates of
major coronary events were proportional to the mean heart dose
and continued into the third decade after surgery (1). All study
patients were treated with the conventional 3-dimensional confor-
mal radiotherapy technique (3D-CRT), which has been reported
to increase radiation dose to the heart despite physician attempts
to shield the heart from the radiation (2). Indeed, a higher risk
of cardiac mortality was observed among patients with left-sided
breast cancer compared to the ones with right breast cancer fol-
lowing post-operative irradiation (3). Even though recent studies
suggest that the mortality of left breast irradiation was not dif-
ferent than the right breast after 1993, long-term cardiac damage
frequently occurs after two decades, prompting some caution that
these adverse events may arise in the next decade as the patients
become older (4). Significant reduction in myocardial function
was observed in patients with left breast cancer following radi-
ation dose as low as 3 Gy 2 months after treatment (5). Set up
variation with two tangent fields has been demonstrated to expose
the myocardium to a higher dose of radiation leading to myocar-
dial hypoperfusion (6). Radiation-induced myocardial damage is
often clinically silent even when there was significant reduction of
the left ventricular ejection fraction (7). The damage to the heart
may be worse in patients with pre-existing cardiovascular con-
ditions such as high blood pressure or left ventricle dysfunction
(8). In addition, in patients who required adjuvant chemotherapy
in addition to radiation following breast cancer surgery, cardiac
toxicity may be compounded from the radiosensitization effect of
chemotherapy.
Cardiac toxicity following chemotherapy and radiotherapy for
breast cancer occurs late and increases on long-term follow-up
with serial echocardiography (9). As radiation damage to the
myocardium is primarily due to the inflammation and scarring of
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the heart microvascular structure, which leads to hypoperfusion
and ventricular dysfunction, minimizing irradiation of the normal
heart without compromise of target coverage should be the pri-
mary objective in patients with left-sided breast cancer (10, 11). To
achieve this goal, new radiotherapy techniques such as intensity-
modulated radiotherapy (IMRT) and image-guided radiotherapy
(IGRT) have been introduced to limit cardiac toxicity.
INTENSITY-MODULATED RADIOTHERAPY FOR CARDIAC
PROTECTION IN PATIENTS WITH LEFT-SIDED BREAST
CANCER
The ability to modulate radiation beams during radiation treat-
ment has been investigated extensively to spare normal organs
from excessive radiation. Breast cancer IMRT is usually deliv-
ered using dynamic multileaf collimation (MLC) or as a limited
number of static MLC segments delivered sequentially in the
step-and-shoot fashion. The beam modulation allows for a homo-
geneous dose distribution within the breast avoiding areas of high
dose leading to less side effects and possibly better cosmesis in
randomized studies (12, 13). Compared to 3D-CRT, IMRT may
significantly reduce radiation dose to the myocardium in patients
with left-sided breast cancer when the internal mammary nodes
were included in the radiation fields because of the steep dose
fall off away from the target volume. The average heart volume
receiving more than 30 Gy were 2.6 and 16.4% for IMRT and 3D-
CRT, respectively (14). The superiority of IMRT over 3D-CRT
for left-sided breast cancer was particularly beneficial in patients
with a significant heart volume (more than 1 cm) included in the
radiation fields. The mean percentage of the heart volume receiv-
ing more than 60% of the prescription dose was 2.2 and 4.4%
for IMRT and 3D-CRT, respectively (15). The benefit of IMRT
to decrease cardiac irradiation while improving target coverage
and dose homogeneity was also corroborated in other dosimet-
ric studies (16). As randomized studies demonstrated a significant
reduction of side effects during radiotherapy for breast cancer with
IMRT compared to 3D-CRT, it is quite possible that long-term car-
diac complications may also be reduced in the future with IMRT
given its cardiac sparing properties. However, long-term follow-up
is needed to confirm this hypothesis.
POTENTIAL ADVANTAGES OF IGRT FOR CARDIAC SPARING
IN PATIENTS WITH LEFT-SIDED BREAST CANCER
Image-guided radiotherapy is a tool that can be used in different
radiotherapy treatments, including IMRT that gives the possibility
of reduction of set up margins, with a better sparing of normal
tissue, while promoting dose-escalation to the tumor. Thus, the
visualization of the surgical tumor bed as outlined by the fidu-
cial markers or the lumpectomy cavity and the organs at risk
(OAR) during radiotherapy may allow the delivery of a higher
radiation dose to the areas at risk for recurrence while reduc-
ing irradiation of the normal organs such as the heart and lungs.
As an illustration, compared to IMRT, IGRT may substantially
reduce radiation dose to a small organ such as the cochlea without
sacrificing target coverage in patients with head and neck cancer
(17). Preliminary results of IGRT for normal organs sparing in
patients with breast cancer are encouraging. As the lumpectomy
cavity decreases in size during breast irradiation, re-planning for
the tumor boost toward the end of whole breast irradiation may
decrease the volume of the normal breast irradiated to a higher
dose and potentially improve cosmetic results (18). This issue is
particularly important in patients who develop a large seroma as
a complication of surgery. Visualization of the lumpectomy cav-
ity with daily imaging allows the delivery of a higher radiation
dose to the tumor bed while treating the whole breast to a lower
dose with the simultaneous integrated boost (SIB) technique. In
patients with left-sided breast cancers, the volume of the heart irra-
diated to a high radiation dose may be significantly reduced. The
volume of the heart radiated to 30 Gy (V30) and the mean heart
dose were 0.03 and 1.14% and 1.35 and 2.22 Gy for IGRT and 3D-
CRT, respectively (19). The cardiac sparing effect of IGRT over
3D-CRT was also corroborated in another study (20). Treatment
time may also be shortened with the SIB technique as radiation
may be delivered over 28 fractions instead of the conventional 38
fractions (21). Another potential advantage of IGRT over IMRT
is its ability to the monitor the patient breathing pattern during
radiotherapy with pre-treatment imaging such as cone-beam CT
(CBCT). In patients who are able to maintain a deep breath hold in
inspiration, the volume of myocardium irradiated may be signifi-
cantly reduced during radiation because the heart shifts away from
the chest wall (22). The feasibility of IGRT for cardiac sparing in
patients with left-sided breast cancer was investigated in a prospec-
tive study. Nineteen left-sided breast cancer patients were treated
with the deep inspiration breath hold (DIBH) technique during
IGRT. Compared to the free-breathing (FB) technique, DIBH sig-
nificantly reduced radiation dose to the heart. The percentage
of the left ventricle radiated was 28 and 71% for DIBH and FB,
respectively (23). For selected patients with pathological stage T1
infiltrating ductal carcinoma completely resected without nodal
involvement who could lay prone during radiotherapy, the tumor
cavity and margins can also be treated with IGRT to 30 Gy in five
fractions without compromise of loco-regional control (24). As
the prone position allows reduction of radiation dose to the heart
compared to the supine position (25), IGRT may potentially spare
the heart from excessive radiation while shortening the treatment
course in patients with left-sided breast cancer (26). The feasibility
of IGRT to spare the heart in the prone position with an acceler-
ated partial breast radiotherapy regimen was also corroborated
in another study (27). For breast cancer patients with a special
chest anatomy such as pectus excavatum or funnel chest where a
large heart volume is frequently included in the radiation fields,
IGRT may also be beneficial in avoiding excessive cardiac irradia-
tion (28). Thus, daily imaging with IGRT allows delivery of IMRT
through various treatment positions and breathing cycles, which
may improve cardiac sparing without compromise of the target
volume in patients with left-sided breast cancer.
CLINICAL STUDIES OF IGRT FOR BREAST CANCER
TREATMENT
Preliminary studies of IGRT for breast cancer treatment have been
promising. In a phase II study, 50 patients with stage I–III infil-
trating ductal carcinoma of the breast were treated with IGRT in
the supine position with hypofractionation. The whole breast and
lumpectomy cavity were treated to 40.5 and 48 Gy in 15 fractions
with the SIB technique. Daily CBCT was performed to verify the
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patient set up before each treatment. The constraint for the cardiac
dose was D40 less than 3%. In patients with left breast lesions, the
dose to the heart was kept to a maximum dose of 27 Gy. Despite
a shorter treatment course, only one patient developed a grade 3
skin reaction. There were no complications or loco-regional recur-
rences after a median follow-up of 12 months (29). The benefit of
hypofractionated IGRT for breast cancer was also corroborated in
another randomized study (30). In all, 123 stage I and II breast
cancer patients were randomized to IGRT (59) and 3D-CRT (64).
The patients were treated to 42–51 Gy over 3 weeks and 50–66 Gy
over 5–7 weeks with IGRT and 3D-CRT, respectively. Quality of life
(QOL) was assessed with questionnaires at 3 months, and 1, 2, and
3 years after treatment. At 3 months post-radiotherapy, patients
who had IGRT developed less fatigue and had improved physical
and emotional functioning compared to those undergoing 3D-
CRT. After a median follow-up of 26 months, the IGRT group
still had a better QOL score even though the difference was no
longer statistically significant. Thus, despite a shorter treatment
course, IGRT may provide a better QOL for breast cancer patients
possibly because of improved normal organ sparing. In another
randomized study of 59 stage I and II breast cancer patients treated
with IGRT (37) and 3D-CRT (32) treated with a similar fractiona-
tion, cardiac toxicity was similar for both groups (31). Despite the
small number of patients and the short follow-up, these prelimi-
nary studies raised intriguing questions about the potential benefit
of IGRT to decrease treatment toxicity and to improve QOL in
breast cancer patients. It remains to be seen whether the potential
of IGRT to reduce cardiac irradiation for left-sided breast cancer
may translate into long-term reduction of cardiac complications.
IDENTIFICATION OF PATIENTS WHO MAY BENEFIT FROM
IGRT FOR LEFT-SIDED BREAST CANCER
Patients with human epidermal growth factor receptor-2 (Her-2)
positive breast cancer had improved survival when trastuzumab
was added to their chemotherapy regimen. Even though
trastuzumab is well tolerated in most patients, a small proportion
may develop congestive heart failure and left ventricular dysfunc-
tion as complication. As the half-life of trastuzumab is 4 weeks, it
will take 16–20 weeks to be cleared from the body and as a result
may still be present at clinically significant levels at the time of
radiotherapy. Preliminary results suggest that trastuzumab may
potentiate the cardiotoxicity of radiation. Even a mean heart dose
of 10 Gy may increase the risk of low grade cardiac toxicity when
trastuzumab was administered with radiation in patients with left
breast cancer (32). In another study of 95 breast cancer patients
who had radiotherapy and concurrent trastuzumab, 58 patients
experienced left ventricular ejection dysfunction (33). Grade 2
decrease in left ventricular ejection fraction was also observed in
10% of the patients receiving trastuzumab and breast radiother-
apy (34). As radiotherapy should not be delayed in Her-2 positive
breast cancer patients receiving trastuzumab and the long-term
effect of the combined treatment remains unknown, these patients
may benefit from IGRT if the tumor is located in the left breast.
As the risk cardiac toxicity increases over time following treat-
ment with anthracycline-based chemotherapy and radiotherapy
for breast cancer, these patients may also benefit from IGRT to
minimize radiation dose to the myocardium (9). However, as most
chemotherapy agents have cardiac effects, left-sided breast cancer
patients who had a history of chemotherapy and radiotherapy
should be monitored closely to determine any deterioration of
their cardiac function over time (35). Elderly breast cancer patients
(70 years or older) are more likely to have pre-existing cardiovas-
cular morbidities and less likely to receive radiotherapy following
surgery compared to younger patients because of the fear of treat-
ment toxicity (36). The elderly breast cancer patients are more
likely to benefit from a short course of hypofractionated IGRT
to reduce treatment time and to decrease the toxic effect of car-
diac irradiation. Such study should be conducted in the future to
assess the beneficial effect of IGRT for local control and survival
in elderly breast cancer patients.
CONCLUSION
Image-guided radiotherapy is a promising new technique of radi-
ation that may significantly decrease cardiac irradiation in patients
with left-sided breast cancers and potentially decrease long-
term cardiac complications. Future prospective studies should be
performed to verify this hypothesis.
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